Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced its participation in several prominent investor conferences, marking an important opportunity to engage with the financial community and highlight the …
Madrigal Pharmaceuticals Engages with Investors at Key Conferences Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has reported its financial and operational achievements for the third quarter of 2024, highlighting robust net sales and strategic progress with its …
Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has successfully completed enrollment for its MAESTRO-NASH OUTCOMES trial, a critical study evaluating the efficacy of resmetirom in patients with compensated NASH …
Madrigal Pharmaceuticals Advances NASH Treatment with Full Enrollment of MAESTRO-NASH OUTCOMES Trial Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the opening of U.S. …
Madrigal Pharmaceuticals Set to Reveal Q3 2024 Financial Results Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) will take part in a fireside chat at the upcoming H.C. Wainwright 8th Annual MASH Virtual Investor Conference.
Madrigal Pharmaceuticals Joins H.C. Wainwright MASH Virtual Investor Conference Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced the appointment of Dr. Michael R. Charlton as Senior Vice President of Clinical Development, effective October 1, 2024. This key addition …
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as SVP of Clinical Development Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has revealed promising patient-reported outcomes showing that Rezdiffra (resmetirom) significantly enhances health-related quality of life (HRQL) for individuals with nonalcoholic steatohepatitis (NASH) with …
Madrigal Pharmaceuticals Announces Positive Quality of Life Outcomes for Rezdiffra in NASH Treatment Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 10:45 A.M. ET.
Madrigal Pharmaceuticals to Present at Global Healthcare Conference Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its financial results for the second quarter ending June 30, 2024. The company reported net sales of $14.6 million, driven by …
Madrigal Pharmaceuticals Reports Q2 2024 Financial Results and Provides Updates Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has named Shannon Kelley as its new General Counsel, effective August 5, 2024.
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel Read More